非小细胞肺癌对EGFR-TKIs获得性耐药的中西医策略研究进展  

Treatment strategy of traditional Chinese and Western medicine for EGFR-TKIs acguired drug-resistance in treating nonsmall-cell lung cancer

作　　者：郭会[1] 潘方舒[1] 吴志强[1] 舒琦瑾[2] 

机构地区：[1]浙江中医药大学第一临床医学院,浙江杭州310053 [2]浙江中医药大学附属第一医院肿瘤科,浙江杭州310006

出　　处：《山西中医学院学报》2016年第2期76-78,F0003,共4页Journal of Shanxi College of Traditional Chinese Medicine

摘　　要：对于非小细胞肺癌EGFR基因突变阳性患者,EGFR-TKIs是治疗的基石。然而,在取得疗效卓越的同时,获得性耐药问题也相继出现。针对这些TKIs获得性耐药患者,后续如何治疗尚未有标准治疗方案,如何有效克服获得性耐药成为大家关注的焦点。目前,针对TKIs获得性耐药的中药研究越来越多,部分取得较好疗效。通过研究非小细胞肺癌EGFR基因突变阳性患者产生EGFR-TKIs获得性耐药的机制以及耐药后采取的中西医治疗策略,希望能为临床治疗提供一定参考。For non-small cell lung cancer patients with EGFR mutation-positive,EGFR-TKIs is the cornerstone of treatment. However,acquired resistance problems have also appeared with the excellence efficacy. For patients with acquired resistance to TKIs,there are not been a standard treatment options of subsequent treatments and how to effectively overcome acquired drug resistance has become the focus of everyone′ s attention.Currently,traditional Chinese medicine researchs for acquired resistance are becoming more and more,some achieve better results.In this review,we present main mechanisms about aquired EGFR-TKIs resistance with non-small-cell lung caner and show developments on traditional Chinese and western medicine in overcoming EGFR-TKIs resistance,hoping to provide a reference for clinical treatment.

关 键 词：非小细胞肺癌 表皮生长因子受体酪氨酸激酶抑制剂 获得性耐药 中西医结合 

分 类 号：R734[医药卫生—肿瘤]